Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

PHASE3CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

April 30, 2015

Conditions
Actinic Keratosis
Interventions
DRUG

BF-200 ALA gel

BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.

DRUG

Placebo to BF-200 ALA gel

The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.

PROCEDURE

Photodynamic therapy with BF-RhodoLED

After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.

Trial Locations (1)

Unknown

Dermatologisches Zentrum Bonn Friedensplatz, Bonn

Sponsors
All Listed Sponsors
lead

Biofrontera Bioscience GmbH

INDUSTRY

NCT01966120 - Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) | Biotech Hunter | Biotech Hunter